1. Two isoforms of calcitonin gene-related peptide (CGRP) exist, each encoded by a distinct gene. Which of the following correctly identifies the genes encoding alpha-CGRP and beta-CGRP, describes how alpha-CGRP is produced from its gene, and identifies the primary site of beta-CGRP expression?
A) Alpha-CGRP is encoded by the CALCB gene on chromosome 11 and is produced by constitutive transcription without alternative splicing; beta-CGRP is encoded by the CALCA gene and is expressed primarily in the trigeminal ganglion, making it the pharmacologically relevant isoform in migraine
B) Alpha-CGRP is encoded by the CALCRL gene through differential promoter usage that directs tissue-specific expression in peripheral sensory neurons; beta-CGRP is encoded by the CALCB gene and is expressed in the hypothalamus, where it modulates the autonomic triggers of migraine attacks
C) Both alpha-CGRP and beta-CGRP are encoded by the same gene (CALCA) through alternative splicing at exon 4; alpha-CGRP is the product of neuronal splicing and beta-CGRP is the product of thyroid C-cell splicing; the enteric nervous system expresses neither isoform and obtains CGRP exclusively from blood-borne alpha-CGRP transported across the gut mucosa
D) Alpha-CGRP is encoded by the CALCA gene on chromosome 11 and is produced by alternative splicing of the calcitonin gene transcript — the same primary transcript that produces calcitonin in thyroid C-cells when spliced differently — and predominates in the peripheral and central nervous system including the trigeminal ganglion; beta-CGRP is encoded by the distinct CALCB gene and is expressed primarily in the enteric nervous system
E) Alpha-CGRP is encoded by the CALCA gene and is produced exclusively in trigeminal ganglion neurons through neuron-specific RNA editing of a pre-mRNA that otherwise encodes only calcitonin; beta-CGRP is encoded by the CALCB gene and is expressed in both the enteric nervous system and the trigeminal ganglion, making it equipotent with alpha-CGRP at the CLR/RAMP1 receptor in migraine pathophysiology
ANSWER: D
Rationale:
Two isoforms of CGRP are produced from two distinct genes. Alpha-CGRP is encoded by the CALCA gene located on chromosome 11 — the same gene that encodes calcitonin. The primary CALCA transcript undergoes tissue-specific alternative splicing: in thyroid C-cells, exon 4 is included and the transcript is processed to produce calcitonin; in neurons, exon 4 is skipped and the transcript is instead processed to produce the 37-amino-acid alpha-CGRP peptide. Alpha-CGRP predominates in the peripheral and central nervous system, including the pseudounipolar neurons of the trigeminal ganglion where it is the pharmacologically relevant isoform in migraine. Beta-CGRP is encoded by the structurally related but distinct CALCB gene and is expressed primarily in the enteric nervous system, where CLR/RAMP1 receptors on enteric neurons modulate gastrointestinal motility — the basis for the higher constipation rate observed with erenumab, which blocks the receptor and therefore also blocks enteric beta-CGRP signaling.
Option A: Option A is incorrect because the gene assignments are reversed: alpha-CGRP is encoded by CALCA (not CALCB) and beta-CGRP is encoded by CALCB (not CALCA); alpha-CGRP from the trigeminal ganglion is the migraine-relevant isoform, not beta-CGRP.
Option B: Option B is incorrect because alpha-CGRP is encoded by CALCA (not CALCRL — CALCRL encodes calcitonin receptor-like receptor, which is the receptor subunit, not the ligand), and production of alpha-CGRP involves alternative splicing, not differential promoter usage; beta-CGRP is expressed primarily in the enteric nervous system, not the hypothalamus.
Option C: Option C is incorrect because alpha-CGRP and beta-CGRP are encoded by two distinct genes (CALCA and CALCB respectively), not by the same gene through alternative splicing; the enteric nervous system does express beta-CGRP endogenously rather than obtaining it from blood-borne sources.
Option E: Option E is incorrect because alpha-CGRP production from CALCA involves alternative splicing of the primary transcript (not RNA editing), and beta-CGRP is expressed primarily in the enteric nervous system rather than co-expressed with alpha-CGRP in the trigeminal ganglion as an equipotent isoform in migraine.
2. Calcitonin receptor-like receptor (CLR) is a seven-transmembrane G protein-coupled receptor that forms the core of the CGRP receptor. Which of the following most accurately describes the requirement for CLR surface expression and the consequence if this requirement is not met?
A) CLR reaches the plasma membrane independently and constitutively in all cell types that express its gene; receptor activity-modifying protein 1 (RAMP1) is only required after surface expression to stabilize the receptor in its active conformation and prevent constitutive internalization by beta-arrestin
B) CLR cannot reach the plasma membrane on its own and requires RAMP1 as an obligate chaperone protein; without RAMP1, CLR is retained in the endoplasmic reticulum and does not traffic to the cell surface, meaning no functional CGRP receptor exists at the membrane in the absence of RAMP1 co-expression
C) CLR reaches the plasma membrane independently but with low efficiency; RAMP1 acts as an allosteric activator that increases CLR surface expression by approximately 3-fold by preventing ubiquitin-mediated proteasomal degradation of CLR in the Golgi apparatus, and CGRP can still activate membrane-resident CLR in the complete absence of RAMP1 with reduced potency
D) CLR requires dimerization with a second CLR molecule to exit the endoplasmic reticulum; the CLR homodimer then associates with RAMP1 at the plasma membrane to form the functional trimeric CGRP receptor complex; RAMP1 is not required for surface expression but is required for high-affinity CGRP binding to the preformed CLR homodimer
E) CLR is a constitutively active receptor that reaches the plasma membrane without any chaperone requirement; RAMP1 functions not as a chaperone but as an inverse agonist that suppresses CLR's constitutive activity, and CGRP binding displaces RAMP1 from its inhibitory binding site to allow receptor activation
ANSWER: B
Rationale:
CLR is unusual among G protein-coupled receptors in that it cannot traffic to the plasma membrane independently. CLR requires RAMP1 as an obligate membrane chaperone: RAMP1 escorts CLR from the endoplasmic reticulum through the Golgi apparatus to the plasma membrane, and without RAMP1 co-expression, CLR is retained intracellularly and no functional receptor is present at the cell surface. This requirement for a chaperone protein is a defining pharmacological feature of the CLR/RAMP family, distinguishing it from most other GPCRs that traffic independently. The RAMP1 requirement is not merely a matter of efficiency — it is obligate for surface expression. Once assembled at the membrane, RAMP1 also shapes the extracellular ligand-binding interface, determining CGRP selectivity over other CLR ligands. The erenumab binding epitope is formed at the CLR/RAMP1 interface that is only accessible once the heterodimer is assembled at the surface.
Option A: Option A is incorrect because CLR does not traffic to the plasma membrane independently; RAMP1 is not merely a post-surface stabilizer but is required for CLR to exit the endoplasmic reticulum and reach the cell surface.
Option C: Option C is incorrect because RAMP1 is not simply an allosteric enhancer of surface expression that increases trafficking efficiency by 3-fold while allowing residual CLR function without it; RAMP1 is obligate for surface expression of CLR, and there is no functional CLR receptor at the membrane in its absence.
Option D: Option D is incorrect because CLR does not form a homodimer to exit the endoplasmic reticulum; it is a monomer that requires RAMP1 as its obligate heterodimeric partner, and the functional CGRP receptor is a heterodimer of CLR and RAMP1, not a CLR homodimer with RAMP1 added secondarily.
Option E: Option E is incorrect because CLR is not constitutively active and does not reach the plasma membrane without RAMP1; RAMP1 is not an inverse agonist suppressing constitutive activity but an obligate structural partner required for surface expression and ligand-binding competence.
3. When CGRP binds the CLR/RAMP1 heterodimer on vascular smooth muscle, it activates an intracellular signaling cascade. Which of the following correctly identifies the G protein coupled to CLR/RAMP1 and the immediate second messenger generated downstream of its activation?
A) CLR/RAMP1 couples to Gs; Gs activates adenylyl cyclase, generating cyclic AMP (cAMP) as the second messenger; cAMP then activates protein kinase A (PKA), which phosphorylates downstream targets including KATP channels and myosin light chain kinase to produce vasodilation
B) CLR/RAMP1 couples to Gq; Gq activates phospholipase C, generating inositol trisphosphate (IP3) and diacylglycerol (DAG) as second messengers; IP3 releases calcium from the sarcoplasmic reticulum, and DAG activates protein kinase C to produce the vasodilatory response
C) CLR/RAMP1 couples to Gi; Gi inhibits adenylyl cyclase, reducing intracellular cAMP; the fall in cAMP disinhibits protein kinase A, producing paradoxical kinase activation that drives vasodilation through an inverted second messenger cascade
D) CLR/RAMP1 couples to G12/13; G12/13 activates RhoGEF, which activates RhoA and its downstream effector ROCK (Rho-associated protein kinase); ROCK phosphorylates myosin light chain phosphatase to inhibit it, maintaining myosin phosphorylation and producing the sustained vasodilation characteristic of CGRP signaling
E) CLR/RAMP1 couples to Gs but generates cyclic GMP (cGMP) rather than cAMP, because Gs in vascular smooth muscle activates soluble guanylyl cyclase rather than adenylyl cyclase; cGMP then activates protein kinase G (PKG) to produce vasodilation through the same pathway activated by nitric oxide
ANSWER: A
Rationale:
The CLR/RAMP1 CGRP receptor couples to the stimulatory G protein Gs. Gs activates adenylyl cyclase, which catalyzes the conversion of ATP to cyclic AMP (cAMP). Elevated intracellular cAMP activates protein kinase A (PKA), which phosphorylates multiple downstream targets in vascular smooth muscle cells: ATP-sensitive potassium (KATP) channels — increasing potassium efflux and hyperpolarizing the membrane — and myosin light chain kinase — reducing its activity and thereby reducing contractile force. The net result is smooth muscle relaxation and vasodilation of cranial dural and cerebral vessels. This Gs/cAMP/PKA cascade is the canonical signaling pathway downstream of CLR/RAMP1 and is the molecular basis for CGRP's potency as a cranial vasodilator.
Option B: Option B is incorrect because CLR/RAMP1 couples to Gs (not Gq); the Gq/phospholipase C/IP3/DAG pathway generates calcium-mediated contraction rather than vasodilation, which is the opposite of CGRP's vascular effect.
Option C: Option C is incorrect because CLR/RAMP1 couples to Gs (stimulatory), not Gi (inhibitory); Gi inhibits adenylyl cyclase and reduces cAMP, and the paradoxical disinhibition mechanism described does not correspond to any established signaling pathway for CGRP.
Option D: Option D is incorrect because CLR/RAMP1 does not couple to G12/13; the G12/13-RhoA-ROCK pathway inhibits myosin light chain phosphatase and maintains smooth muscle contraction, which is a vasoconstrictive mechanism used by angiotensin II and endothelin, opposite to CGRP's vasodilatory effect.
Option E: Option E is incorrect because Gs activates adenylyl cyclase to generate cAMP, not soluble guanylyl cyclase to generate cGMP; cGMP generation via soluble guanylyl cyclase is the mechanism of nitric oxide and natriuretic peptide signaling, not CGRP/CLR/RAMP1 signaling.
4. The gepants — ubrogepant, rimegepant, atogepant, and zavegepant — share a defining mechanism of action that distinguishes them pharmacologically from the triptans. Which of the following most accurately describes the gepant mechanism at the molecular level and identifies the receptor activity that triptans possess but gepants lack?
A) Gepants are irreversible covalent antagonists at CLR/RAMP1 that permanently occupy the CGRP binding pocket until new receptor protein is synthesized; triptans are reversible competitive antagonists at CLR/RAMP1 that can be displaced by high CGRP concentrations during a severe migraine attack, explaining why triptans are less effective than gepants in high-burden migraine
B) Gepants are positive allosteric modulators of CLR/RAMP1 that enhance receptor desensitization following CGRP binding, reducing signal duration without blocking initial receptor activation; triptans are negative allosteric modulators that both block CGRP binding and activate 5-HT1B receptors on vascular smooth muscle to produce vasoconstriction
C) Gepants are competitive, reversible antagonists at the CLR/RAMP1 CGRP receptor — they occupy the receptor binding pocket and block CGRP-mediated activation without activating the receptor themselves; the receptor activity that triptans possess but gepants entirely lack is 5-HT1B agonism, which produces direct arterial vasoconstriction and is the basis for the triptan contraindication in cardiovascular disease
D) Gepants are selective inverse agonists at CLR/RAMP1 that suppress constitutive receptor activity below basal levels; triptans are partial agonists at CLR/RAMP1 that produce submaximal vasodilation compared to CGRP, and their 5-HT1B agonism produces additional vasoconstriction that together with partial CLR/RAMP1 activation produces the net vasoconstriction observed clinically
E) Gepants are non-competitive antagonists at CLR/RAMP1 that bind an allosteric site on the RAMP1 extracellular domain remote from the CGRP binding pocket; because the antagonism is non-competitive, it cannot be overcome by increasing CGRP concentrations, making gepants more effective than triptans in migraine attacks with very high CGRP release
ANSWER: C
Rationale:
All four approved gepants are competitive, reversible antagonists at the CLR/RAMP1 CGRP receptor. They occupy the receptor binding pocket at the CLR/RAMP1 interface — the same site where the CGRP peptide normally binds — and competitively block CGRP from activating the receptor. As pure antagonists, they produce no receptor activation themselves and have no intrinsic agonist activity at CLR/RAMP1. Because their antagonism is competitive and reversible, they can be displaced by sufficiently high CGRP concentrations, and their effect is fully reversible as plasma drug concentrations decline. The critical pharmacological distinction from triptans is the absence of 5-HT1B agonism: triptans (sumatriptan, rizatriptan, eletriptan, and others) are 5-HT1B/1D receptor agonists, and 5-HT1B receptor activation on coronary and peripheral vascular smooth muscle produces direct arterial vasoconstriction. This vasoconstrictive activity is the basis for the triptan contraindication in ischemic heart disease, stroke, peripheral vascular disease, and uncontrolled hypertension. Gepants have no 5-HT receptor activity whatsoever, which is why they carry no cardiovascular contraindications based on vasoconstriction.
Option A: Option A is incorrect because gepants are competitive reversible antagonists, not irreversible covalent antagonists; triptans do not act at CLR/RAMP1 and are not competitive antagonists at the CGRP receptor — they are 5-HT1B/1D agonists with no CLR/RAMP1 activity.
Option B: Option B is incorrect because gepants are receptor antagonists (they block activation), not positive allosteric modulators that enhance desensitization; triptans are 5-HT1B agonists, not negative allosteric modulators at CLR/RAMP1.
Option D: Option D is incorrect because gepants do not suppress constitutive receptor activity as inverse agonists, and triptans are not partial agonists at CLR/RAMP1 — triptans have no meaningful CLR/RAMP1 activity and act through 5-HT1B/1D receptors.
Option E: Option E is incorrect because gepants are competitive antagonists that occupy the orthosteric CGRP binding pocket, not non-competitive allosteric antagonists at a remote RAMP1 site; competitive antagonism can in principle be overcome by very high agonist concentrations, while non-competitive antagonism cannot — the option reverses the established gepant mechanism.
5. Erenumab (Aimovig) is one of four approved anti-CGRP monoclonal antibodies for migraine prevention. Which of the following correctly identifies erenumab's IgG subclass, its molecular target within the CGRP pathway, and its approved dosing schedule?
A) Erenumab is a humanized IgG1 antibody that targets the CGRP ligand by binding to the C-terminal amide region of both alpha-CGRP and beta-CGRP; it is dosed at 70 or 140 mg intravenously quarterly, with the IV route chosen to achieve immediate peak concentrations that suppress CGRP during the high-release period following cortical spreading depression
B) Erenumab is a fully human IgG4 antibody that targets the CGRP receptor by binding to the RAMP1 extracellular domain alone, independent of CLR; it is dosed at 70 or 140 mg subcutaneously every 3 months, with the quarterly schedule reflecting its longer half-life compared to other anti-CGRP antibodies due to IgG4's superior FcRn recycling efficiency
C) Erenumab is a humanized IgG2a antibody that targets the CGRP ligand alpha-CGRP with high affinity but no affinity for beta-CGRP; it is dosed at 70 mg subcutaneously monthly, with the 140 mg dose reserved for patients with chronic migraine who require higher receptor occupancy to overcome the elevated CGRP levels characteristic of the chronic migraine state
D) Erenumab is a fully human IgG2 antibody that targets the CGRP ligand (the peptide itself) rather than the receptor; it is dosed at 70 or 140 mg subcutaneously monthly; because it targets the ligand, erenumab captures circulating CGRP before it can reach the CLR/RAMP1 receptor, and patients who fail erenumab are unlikely to respond to other ligand-targeting antibodies through the same mechanism
E) Erenumab is a fully human IgG2 antibody that targets the CGRP receptor — specifically the extracellular domain formed at the CLR/RAMP1 interface — rather than the CGRP peptide itself; it is dosed at 70 or 140 mg subcutaneously once monthly; its IgG2 subclass was selected to minimize Fc receptor engagement and reduce complement activation and antibody-dependent cellular cytotoxicity, appropriate for a long-term monthly preventive agent
ANSWER: E
Rationale:
Erenumab (Aimovig) is a fully human IgG2 monoclonal antibody. It is the only approved anti-CGRP antibody that targets the receptor rather than the CGRP ligand — specifically, it binds an extracellular epitope formed at the CLR/RAMP1 interface, which is unique to the assembled heterodimer and overlaps with the CGRP peptide binding site, achieving competitive antagonism at the receptor level. It is administered subcutaneously at either 70 mg or 140 mg once monthly. The IgG2 subclass was deliberately selected because IgG2 has reduced affinity for Fcγ receptors compared to IgG1, minimizing complement activation and antibody-dependent cellular cytotoxicity — effector functions that serve no therapeutic purpose for a purely blocking antibody and whose minimization reduces the risk of injection site inflammation and immune activation during long-term monthly use.
Option A: Option A is incorrect because erenumab is fully human (not humanized), targets the receptor (not the ligand), and is administered subcutaneously monthly (not IV quarterly); IV quarterly administration describes eptinezumab.
Option B: Option B is incorrect because erenumab is IgG2 (not IgG4), targets the CLR/RAMP1 interface (not RAMP1 alone), and is dosed monthly (not quarterly); quarterly dosing describes fremanezumab (675 mg) and eptinezumab (100 or 300 mg IV).
Option C: Option C is incorrect because erenumab is fully human IgG2 (not humanized IgG2a — IgG2a is the subclass of fremanezumab), and erenumab targets the receptor, not the CGRP ligand; additionally, the 140 mg dose is approved for both episodic and chronic migraine, not restricted to chronic migraine alone.
Option D: Option D is incorrect because erenumab targets the CGRP receptor (CLR/RAMP1), not the CGRP ligand; the ligand-targeting antibodies are fremanezumab, galcanezumab, and eptinezumab; this mechanistic distinction is the defining feature of erenumab within the class.
6. Ubrogepant (Ubrelvy) was the first oral gepant approved for acute migraine treatment. Which of the following correctly identifies ubrogepant's oral bioavailability, primary metabolic pathway, approved indication, and approved dose range?
A) Ubrogepant has an oral bioavailability of approximately 44 percent, is metabolized primarily by CYP2D6, is approved for both acute migraine treatment and preventive treatment, and is dosed at 10, 30, or 60 mg once daily for prevention or 50 mg for acute use
B) Ubrogepant has an oral bioavailability of approximately 64 percent, is a P-glycoprotein substrate but not a significant CYP substrate, is approved for acute migraine treatment only, and is dosed at 75 mg as a single orally disintegrating tablet with a second dose permitted at 2 hours if needed
C) Ubrogepant has an oral bioavailability of approximately 7 percent due to extensive hepatic first-pass glucuronidation by UGT1A3, is approved for acute migraine treatment only, and is dosed at 50 or 100 mg orally with a second dose permitted at 2 hours if needed; strong UGT1A3 inhibitors dramatically increase ubrogepant exposure and are contraindicated
D) Ubrogepant has an oral bioavailability of approximately 7 percent due to extensive first-pass metabolism by CYP3A4; it is approved for acute migraine treatment only and is dosed at 50 or 100 mg orally, with a second dose of the same strength permitted at 2 hours if needed (maximum 200 mg per day); strong CYP3A4 inhibitors are contraindicated due to the dramatic increase in ubrogepant exposure they produce
E) Ubrogepant has an oral bioavailability of approximately 7 percent, is metabolized by CYP3A4, and is approved for both acute migraine treatment (100 mg) and preventive treatment (25 mg once daily); the low bioavailability at the preventive dose reflects adequate systemic exposure for continuous CGRP receptor blockade because trough concentrations at 25 mg daily remain above the minimum effective receptor occupancy threshold
ANSWER: D
Rationale:
Ubrogepant (Ubrelvy) has an oral bioavailability of approximately 7 percent, which is among the lowest of the approved gepants. This low bioavailability results from extensive first-pass metabolism by CYP3A4 in the intestinal wall and liver, which metabolizes approximately 93 percent of the absorbed dose before it reaches systemic circulation. Despite this low bioavailability, therapeutic plasma concentrations are achieved at the approved doses because the dose was calibrated for this extraction ratio. Ubrogepant is approved exclusively for acute migraine treatment — it has no preventive indication — and is dosed at 50 or 100 mg orally as a single dose, with a second dose of the same strength permitted 2 hours after the first if needed, for a maximum daily dose of 200 mg. Strong CYP3A4 inhibitors (clarithromycin, ketoconazole, itraconazole) are contraindicated because they dramatically increase ubrogepant systemic exposure by reducing first-pass extraction.
Option A: Option A is incorrect because ubrogepant's oral bioavailability is approximately 7 percent (not 44 percent — 44 percent is atogepant's bioavailability), it is metabolized by CYP3A4 (not CYP2D6), and it is approved for acute use only (not both acute and preventive).
Option B: Option B is incorrect because 64 percent bioavailability describes rimegepant (not ubrogepant), and the 75 mg orally disintegrating tablet describes rimegepant; ubrogepant uses conventional oral tablets at 50 or 100 mg.
Option C: Option C is incorrect because ubrogepant's low bioavailability is due to CYP3A4 metabolism, not UGT1A3 glucuronidation; UGT1A3 inhibitors are not relevant to the ubrogepant drug interaction profile, and strong CYP3A4 inhibitors (not UGT inhibitors) are the agents specifically contraindicated.
Option E: Option E is incorrect because ubrogepant does not hold a preventive indication and has no approved 25 mg once-daily preventive dose; the preventive oral gepants are rimegepant (75 mg every other day) and atogepant (10, 30, or 60 mg once daily).
7. Rimegepant (Nurtec ODT) is the only gepant with a dual FDA approval for both acute and preventive migraine treatment. Which of the following correctly identifies rimegepant's formulation, dosing schedules for each indication, metabolic substrates, and the practical clinical advantage of its formulation for patients with nausea?
A) Rimegepant is a conventional oral tablet available in 75 mg strength; it is dosed at 75 mg as a single dose for acute treatment and 150 mg once daily for prevention; it is a CYP3A4 substrate but not a P-glycoprotein substrate; its clinical advantage over other oral gepants is its faster dissolution rate in gastric fluid, which produces therapeutic plasma concentrations 30 minutes faster than competing formulations
B) Rimegepant is an orally disintegrating tablet (ODT) that dissolves on the tongue; it is dosed at 75 mg as a single dose for acute migraine treatment and 75 mg every other day for preventive treatment; it is a substrate of both CYP3A4 and P-glycoprotein; its ODT formulation is advantageous for patients who experience nausea or vomiting during migraine attacks because it dissolves without requiring water and absorbs without needing to swallow a conventional tablet
C) Rimegepant is an orally disintegrating tablet dosed at 50 or 100 mg for acute treatment and 75 mg once daily for prevention; it is metabolized exclusively by CYP2C19, and patients who are CYP2C19 poor metabolizers require dose reduction to 50 mg for both acute and preventive indications to avoid supratherapeutic exposure
D) Rimegepant is available as both an orally disintegrating tablet and a conventional oral tablet; the ODT is approved for acute treatment (75 mg single dose) while the conventional tablet is approved for preventive use (75 mg once daily); the two formulations have different pharmacokinetic profiles because the ODT achieves direct buccal mucosal absorption bypassing first-pass metabolism entirely, resulting in near-100 percent bioavailability for the preventive indication
E) Rimegepant is an orally disintegrating tablet dosed at 75 mg as a single dose for acute treatment; it does not hold a preventive indication and is distinguished from atogepant solely by its ODT formulation; both rimegepant and atogepant are CYP3A4 substrates, but rimegepant's higher bioavailability of 64 percent compared to atogepant's 44 percent makes it the preferred acute gepant for patients with gastroparesis
ANSWER: B
Rationale:
Rimegepant (Nurtec ODT) is formulated as an orally disintegrating tablet that dissolves on the tongue without requiring water. It is the only gepant with dual FDA approval: 75 mg as a single dose for acute migraine treatment, and 75 mg every other day for preventive treatment. Rimegepant is a substrate of both CYP3A4 and P-glycoprotein, and co-administration with strong CYP3A4 inhibitors is not recommended due to increased exposure. The ODT formulation offers a practical clinical advantage for patients who experience prominent nausea or vomiting during migraine attacks: because it dissolves on the tongue and does not require swallowing a conventional tablet with water, it can be administered even when nausea would prevent reliable oral tablet ingestion. Its oral bioavailability of approximately 64 percent reflects absorption through the gastrointestinal tract after the dissolved material is swallowed.
Option A: Option A is incorrect because rimegepant is an ODT (not a conventional tablet), the preventive dose is 75 mg every other day (not 150 mg once daily), and rimegepant is a P-gp substrate in addition to being a CYP3A4 substrate; dissolution speed in gastric fluid is not its defined clinical advantage.
Option C: Option C is incorrect because rimegepant is dosed at 75 mg for both acute and preventive use (not 50 or 100 mg for acute), the preventive schedule is every other day (not once daily), and rimegepant is metabolized by CYP3A4 (not exclusively CYP2C19); CYP2C19 poor metabolizer dose adjustments are not specified in rimegepant's prescribing information.
Option D: Option D is incorrect because rimegepant is not available in two separate formulations for different indications — it is a single ODT formulation approved for both acute and preventive use; the ODT does not achieve direct buccal mucosal absorption bypassing first-pass metabolism, and its bioavailability of approximately 64 percent reflects standard gastrointestinal absorption after the dissolved material is swallowed.
Option E: Option E is incorrect because rimegepant does hold both acute and preventive indications — its dual approval is its defining feature — and the characterization of its relationship to atogepant is incomplete; atogepant holds only a preventive indication while rimegepant holds both, which is a clinically meaningful distinction beyond formulation differences.
8. Atogepant (Qulipta) is an oral gepant approved exclusively for migraine prevention. Which of the following correctly identifies atogepant's approved dose range, its indication scope, and the dose adjustment required when a strong CYP3A4 inhibitor is co-administered?
A) Atogepant is approved for preventive treatment only (no acute migraine indication) at doses of 10, 30, or 60 mg once daily; when co-administered with a strong CYP3A4 inhibitor, the atogepant dose should be reduced to 10 mg once daily because CYP3A4 inhibition substantially increases atogepant plasma exposure at the standard 30 or 60 mg doses; conversely, strong CYP3A4 inducers reduce atogepant exposure and may require use of the 60 mg dose
B) Atogepant is approved for both acute and preventive migraine treatment; for acute use it is dosed at 60 mg as a single dose, and for prevention at 10 or 30 mg once daily; strong CYP3A4 inhibitors require increasing the preventive dose to 60 mg to compensate for the reduction in free drug fraction caused by CYP3A4 inhibitor-mediated plasma protein displacement
C) Atogepant is approved for preventive treatment only at 30 or 60 mg once daily; the 10 mg dose was studied but not approved due to inadequate efficacy in phase 3 trials; dose adjustment with strong CYP3A4 inhibitors consists of halving the prescribed dose (30 mg → 15 mg or 60 mg → 30 mg), and dose splitting is permitted to achieve the reduced exposure targets
D) Atogepant is approved for preventive treatment at 10, 30, or 60 mg once daily and for acute treatment at 120 mg as a single dose; the high acute dose reflects its lower oral bioavailability compared to ubrogepant, requiring a higher milligram amount to achieve equivalent CLR/RAMP1 receptor occupancy; no CYP3A4 dose adjustment is needed because atogepant's bioavailability of 44 percent is achieved through P-glycoprotein-independent passive absorption
E) Atogepant is approved for preventive treatment only at 10, 30, or 60 mg once daily; no dose adjustment is required with any CYP3A4 inhibitor because atogepant's metabolism is primarily via glucuronidation by UGT1A4, and CYP3A4 inhibitors have no effect on UGT-mediated clearance pathways; atogepant dose adjustment is only required in patients with severe renal impairment (eGFR below 15 mL/min per 1.73 m²)
ANSWER: A
Rationale:
Atogepant (Qulipta) is approved exclusively for migraine prevention and holds no acute migraine treatment indication — it is dosed at 10, 30, or 60 mg once daily for prevention. Atogepant is a CYP3A4 substrate with an oral bioavailability of approximately 44 percent. When a strong CYP3A4 inhibitor is co-administered, CYP3A4 activity is substantially reduced, increasing atogepant plasma AUC and Cmax to levels that may produce supratherapeutic exposure at the standard 30 or 60 mg doses. The prescribing information specifies that the atogepant dose should be reduced to 10 mg once daily when co-administered with a strong CYP3A4 inhibitor. The converse interaction also applies: strong CYP3A4 inducers (such as rifampin) reduce atogepant exposure by increasing its metabolic clearance, and the prescribing information advises either avoiding the combination or using the 60 mg once-daily dose to compensate.
Option B: Option B is incorrect because atogepant does not hold an acute migraine treatment indication — it is preventive only at 10, 30, or 60 mg once daily; CYP3A4 inhibitors increase (not decrease) atogepant exposure by reducing metabolic clearance, requiring dose reduction rather than escalation.
Option C: Option C is incorrect because the 10 mg dose is included in atogepant's approved dose range (it was studied and approved), and the dose adjustment for strong CYP3A4 inhibitors is reduction to 10 mg once daily (not halving of the prescribed dose with dose-splitting).
Option D: Option D is incorrect because atogepant does not hold an acute migraine treatment indication at any dose including 120 mg, and CYP3A4 dose adjustments are explicitly required in atogepant's prescribing information; atogepant is a CYP3A4 substrate, not a drug whose absorption is entirely P-gp-independent without CYP interaction potential.
Option E: Option E is incorrect because atogepant is metabolized by CYP3A4, not primarily by UGT1A4 glucuronidation; CYP3A4 inhibitors do significantly affect atogepant clearance and require dose adjustment, and severe renal impairment dose adjustment is not the primary interaction concern for this CYP3A4 substrate.
9. Zavegepant (Zavzpret) is distinguished from the other approved gepants by its route of administration. Which of the following correctly identifies zavegepant's route, approved indication, dose, approximate time to peak plasma concentration, and the patient population for whom this route is specifically advantageous?
A) Zavegepant is a sublingual tablet approved for acute migraine treatment at 5 mg as a single dose; it achieves peak plasma concentrations within approximately 15 minutes through direct sublingual venous absorption bypassing the portal circulation entirely; it is specifically advantageous for patients who develop severe photophobia early in an attack, as sublingual administration can occur in low-light conditions without requiring coordination of a nasal spray
B) Zavegepant is an intravenous formulation approved for acute migraine treatment at 10 mg administered over 15 minutes; it achieves peak plasma concentrations immediately at infusion completion; it is specifically advantageous for patients in the emergency department with refractory migraine who cannot tolerate any oral or nasal medications, providing a gepant option when parenteral administration is required
C) Zavegepant is an intranasal spray approved for acute migraine treatment at a single 10 mg dose; it bypasses gastrointestinal absorption and hepatic first-pass metabolism, achieving peak plasma concentrations within approximately 30 minutes — faster than oral gepants — and is specifically advantageous for patients who experience prominent early nausea or vomiting during migraine attacks that would impair oral drug absorption, and for patients whose attacks escalate rapidly to severe pain
D) Zavegepant is an intranasal spray approved for both acute treatment (10 mg single dose) and preventive treatment (5 mg once daily); its intranasal route achieves faster onset than oral gepants for acute use, and the lower 5 mg preventive dose maintains continuous low-level CGRP receptor blockade through nasal mucosal absorption that provides sustained systemic concentrations without first-pass metabolism
E) Zavegepant is an intranasal spray approved for acute migraine treatment at 20 mg as a single dose (two actuations of 10 mg each), achieving peak plasma concentrations within approximately 60 minutes; it is specifically advantageous for patients with severe hepatic impairment in whom oral CYP3A4 substrate gepants are contraindicated, as the intranasal route entirely eliminates hepatic drug exposure
ANSWER: C
Rationale:
Zavegepant (Zavzpret) is the first and only intranasal gepant, approved for acute migraine treatment as a single 10 mg intranasal spray dose. Its intranasal route delivers drug directly through the nasal mucosa into the systemic circulation, bypassing gastrointestinal absorption and the hepatic first-pass metabolism that reduces oral gepant bioavailability. This produces a faster onset than oral gepants: zavegepant achieves peak plasma concentrations within approximately 30 minutes of administration, a profile comparable to subcutaneous triptans and substantially faster than the 1.5 to 2 hour Tmax of oral gepants. This pharmacokinetic advantage directly addresses two specific clinical barriers: patients who experience prominent nausea or vomiting early in a migraine attack — making oral medication unreliable — and patients whose attacks escalate rapidly from prodrome to severe pain, requiring faster drug delivery to achieve meaningful symptom relief before the attack is fully established. Zavegepant retains the class-defining absence of vasoconstriction, making it appropriate for patients with cardiovascular risk factors.
Option A: Option A is incorrect because zavegepant is an intranasal spray (not a sublingual tablet) at 10 mg (not 5 mg); sublingual gepants are not among the approved agents, and the 15-minute Tmax through sublingual venous absorption is not an established feature of any approved gepant.
Option B: Option B is incorrect because zavegepant is an intranasal spray (not an intravenous formulation); no gepant is currently approved for intravenous administration — IV delivery is specific to eptinezumab among the CGRP-targeted agents.
Option D: Option D is incorrect because zavegepant is approved only for acute migraine treatment and holds no preventive indication; there is no approved 5 mg once-daily preventive schedule for zavegepant, and the preventive oral gepants are rimegepant and atogepant.
Option E: Option E is incorrect because the approved dose is a single 10 mg intranasal dose (not 20 mg as two actuations); the claim that the intranasal route eliminates hepatic drug exposure entirely is also incorrect — systemically absorbed zavegepant does reach the liver and undergoes some hepatic metabolism, and it is not specifically indicated as the preferred agent for severe hepatic impairment.
10. Fremanezumab (Ajovy) is one of three anti-CGRP monoclonal antibodies that targets the CGRP ligand rather than the receptor. Which of the following correctly identifies fremanezumab's IgG subclass, its molecular target, and both of its approved dosing schedules?
A) Fremanezumab is a fully human IgG2 antibody that targets the CGRP receptor at the RAMP1 extracellular domain; it is dosed at 225 mg subcutaneously monthly, and a quarterly option of 450 mg every 3 months is approved for patients with episodic migraine only; the quarterly dose is lower than three monthly doses combined because a sustained-release depot formulation slows subcutaneous absorption
B) Fremanezumab is a humanized IgG1 antibody that targets the CGRP ligand; it is approved only for monthly dosing at 225 mg subcutaneously; no quarterly option is available because phase 3 data showed the 675 mg quarterly dose produced significantly lower annualized migraine prevention than monthly dosing, leading the FDA to restrict the label to monthly administration
C) Fremanezumab is a humanized IgG4 antibody that targets both the CGRP ligand and the CLR/RAMP1 receptor simultaneously through a bispecific antibody design; it is dosed at 225 mg subcutaneously monthly or 675 mg subcutaneously quarterly; its bispecific design achieves greater CGRP pathway blockade than either erenumab (receptor only) or the other ligand-targeting antibodies (ligand only)
D) Fremanezumab is a humanized IgG2a antibody that targets the CGRP ligand and is dosed at 70 or 140 mg subcutaneously monthly; the two dose options (70 and 140 mg) reflect the same dose-flexibility principle used for erenumab, with 70 mg for episodic migraine and 140 mg for chronic migraine patients requiring greater CGRP neutralization capacity
E) Fremanezumab is a humanized IgG2a antibody that targets the CGRP ligand — binding to both alpha-CGRP and beta-CGRP with high affinity — and is approved for two dosing schedules: 225 mg subcutaneously once monthly, or 675 mg subcutaneously once every 3 months (quarterly); the monthly and quarterly schedules produce equivalent annualized migraine prevention, and the choice between them is based on patient preference for injection frequency
ANSWER: E
Rationale:
Fremanezumab (Ajovy) is a humanized IgG2a monoclonal antibody — humanized meaning it has human framework regions with murine-derived CDRs, and IgG2a is its specific subclass, distinguishing it from erenumab's fully human IgG2. Fremanezumab targets the CGRP ligand itself (the peptide), binding with high affinity to both alpha-CGRP and beta-CGRP, in contrast to erenumab which targets the CLR/RAMP1 receptor. It is approved for two dosing schedules that produce equivalent annualized migraine prevention: 225 mg subcutaneously once monthly (12 injections per year), or 675 mg subcutaneously once every 3 months (quarterly; 3 injections per year). The quarterly 675 mg dose is equivalent to three monthly 225 mg doses given together at the start of each 3-month interval. The choice between schedules is patient-driven, based on preference for injection frequency, and does not affect efficacy.
Option A: Option A is incorrect because fremanezumab is humanized IgG2a (not fully human IgG2), targets the CGRP ligand (not the RAMP1 extracellular domain), and the quarterly dose is 675 mg (not 450 mg) representing three monthly doses; no sustained-release depot formulation is used.
Option B: Option B is incorrect because fremanezumab is IgG1-adjacent in description but is specifically IgG2a, and the quarterly 675 mg option is FDA-approved with equivalent annualized efficacy to monthly dosing — it was not found inferior and is not restricted from any migraine subtype.
Option C: Option C is incorrect because fremanezumab is IgG2a (not IgG4 — IgG4 is galcanezumab's subclass), and it is not a bispecific antibody targeting both the ligand and receptor; it is a monospecific ligand-targeting antibody.
Option D: Option D is incorrect because fremanezumab is dosed at 225 mg monthly or 675 mg quarterly (not 70 or 140 mg monthly — 70 and 140 mg are erenumab's doses); the 70 versus 140 mg distinction in this option belongs to erenumab, not fremanezumab.
11. Galcanezumab (Emgality) is the only anti-CGRP monoclonal antibody with an approved indication beyond migraine. Which of the following correctly identifies galcanezumab's IgG subclass, its migraine dosing regimen including loading dose, its additional approved indication, and the key restriction on that additional indication?
A) Galcanezumab is a fully human IgG1 antibody; for migraine it is dosed at 120 mg subcutaneously monthly without a loading dose; its additional approved indication is chronic cluster headache prevention at 300 mg subcutaneously monthly during the cluster period; the chronic cluster indication was added because CGRP levels are persistently elevated in chronic cluster headache regardless of attack phase
B) Galcanezumab is a humanized IgG2a antibody; for migraine it is dosed at 240 mg subcutaneously as a loading dose followed by 120 mg monthly; its additional approved indication is both episodic and chronic cluster headache prevention at 300 mg subcutaneously monthly, with the same dose used for both cluster subtypes because CGRP plays an equivalent role in both episodic and chronic cluster pathophysiology
C) Galcanezumab is a humanized IgG4 antibody; for migraine it is dosed at 120 mg subcutaneously monthly with no loading dose required; its additional approved indication is episodic cluster headache prevention at 120 mg subcutaneously monthly during the cluster period — the same dose as migraine maintenance — because the required CGRP receptor occupancy is equivalent across both headache disorders
D) Galcanezumab is a humanized IgG4 antibody; for migraine it is dosed at 240 mg subcutaneously as a loading dose (two simultaneous 120 mg injections) followed by 120 mg subcutaneously monthly; its additional approved indication is episodic cluster headache prevention, dosed at 300 mg subcutaneously monthly during the cluster period (three simultaneous 100 mg injections); the indication is restricted to episodic cluster headache and does not extend to chronic cluster headache
E) Galcanezumab is a humanized IgG4 antibody; for migraine it is dosed at 240 mg subcutaneously as a loading dose followed by 120 mg monthly; its additional approved indication is medication overuse headache (MOH) prevention at 240 mg subcutaneously quarterly; the MOH indication was granted because galcanezumab reduces the central sensitization driving analgesic rebound through CGRP blockade at the trigeminal nucleus caudalis
ANSWER: D
Rationale:
Galcanezumab (Emgality) is a humanized IgG4 monoclonal antibody that targets the CGRP ligand. For migraine prevention, it is dosed with a 240 mg loading dose — administered as two simultaneous 120 mg subcutaneous injections at the first visit — followed by 120 mg subcutaneously monthly. The loading dose is used to rapidly achieve near-therapeutic plasma concentrations, compensating for the slow accumulation that would occur with 120 mg alone given the 3 to 7 day Tmax of subcutaneous antibody delivery. Galcanezumab is the only approved anti-CGRP monoclonal antibody with an FDA indication beyond migraine: episodic cluster headache prevention, dosed at 300 mg subcutaneously monthly during the cluster period (administered as three simultaneous 100 mg injections). Two restrictions define this indication: the dose is substantially higher than the migraine maintenance dose (300 mg vs. 120 mg monthly), reflecting the more intense CGRP-driven pathophysiology of cluster attacks; and the indication is limited to episodic cluster headache — it does not extend to chronic cluster headache (defined as attacks occurring without remission periods of 3 months or longer).
Option A: Option A is incorrect because galcanezumab is humanized IgG4 (not fully human IgG1), the migraine regimen requires a 240 mg loading dose (not 120 mg monthly without loading), and the cluster headache indication is restricted to episodic (not chronic) cluster headache.
Option B: Option B is incorrect because galcanezumab is IgG4 (not IgG2a — IgG2a is fremanezumab's subclass), and the cluster headache indication covers episodic cluster only, not both episodic and chronic cluster.
Option C: Option C is incorrect because the migraine regimen does include a 240 mg loading dose (not just 120 mg monthly without loading), and the cluster headache dose is 300 mg monthly during the cluster period (not 120 mg — the higher cluster dose is a defining feature of this indication).
Option E: Option E is incorrect because galcanezumab does not hold an FDA approval for medication overuse headache prevention; the additional approved indication is episodic cluster headache prevention, and no anti-CGRP antibody has a specific MOH prevention indication.
12. Eptinezumab (Vyepti) is unique among the approved anti-CGRP monoclonal antibodies in its route of administration. Which of the following correctly identifies eptinezumab's IgG subclass, molecular target, route of administration, dose options, and dosing frequency?
A) Eptinezumab is a fully human IgG2 antibody that targets the CGRP receptor; it is administered subcutaneously at 100 or 300 mg once quarterly; its quarterly schedule was chosen over monthly dosing because eptinezumab's IgG2 subclass achieves superior FcRn-mediated recycling that extends its effective half-life to approximately 90 days, supporting once-quarterly dosing without loss of trough efficacy
B) Eptinezumab is a humanized IgG1 antibody that targets the CGRP ligand; it is administered intravenously at 100 or 300 mg over 30 minutes, with dosing every 3 months (quarterly); it is the only anti-CGRP monoclonal antibody administered intravenously, and this route produces immediate maximal plasma concentrations at infusion completion — the pharmacokinetic basis for the day-1 migraine prevention onset demonstrated in the PROMISE trials
C) Eptinezumab is a humanized IgG4 antibody that targets the CGRP ligand; it is administered intravenously at 300 mg over 60 minutes monthly; the monthly IV schedule was selected because eptinezumab's IgG4 subclass undergoes Fab-arm exchange that reduces its effective half-life to approximately 14 days, necessitating more frequent dosing than other anti-CGRP antibodies to maintain therapeutic plasma concentrations
D) Eptinezumab is a humanized IgG1 antibody that targets the CGRP receptor; it is administered intravenously at 100 or 300 mg quarterly; because it targets the receptor rather than the ligand, eptinezumab prevents both alpha-CGRP and beta-CGRP from activating CLR/RAMP1, and this dual-isoform blockade is the pharmacological explanation for its superior efficacy compared to the ligand-targeting antibodies in head-to-head clinical trials
E) Eptinezumab is a fully human IgG1 antibody that targets the CGRP ligand; it is administered subcutaneously at 100 or 300 mg monthly using an autoinjector; its primary clinical advantage over the other subcutaneous anti-CGRP antibodies is a shorter Tmax of approximately 24 hours after subcutaneous injection, achieved through a proprietary hyaluronidase co-formulation that accelerates lymphatic absorption from the subcutaneous depot
ANSWER: B
Rationale:
Eptinezumab (Vyepti) is a humanized IgG1 monoclonal antibody that targets the CGRP ligand. It is the only approved anti-CGRP monoclonal antibody administered intravenously: it is given as a 100 or 300 mg intravenous infusion over 30 minutes, with dosing every 3 months (quarterly). The IV route is the defining pharmacokinetic feature of eptinezumab: because the full dose is delivered directly into the systemic circulation without an absorption phase, it achieves immediate maximal plasma concentrations at the completion of the 30-minute infusion. This contrasts with the subcutaneous anti-CGRP antibodies (erenumab, fremanezumab, galcanezumab) that require 3 to 7 days to reach peak plasma concentrations after subcutaneous injection. The immediate Cmax of eptinezumab produces peripheral CGRP blockade from the moment infusion ends, which is the pharmacokinetic explanation for the day-1 migraine prevention onset demonstrated in the PROMISE-1 (episodic migraine) and PROMISE-2 (chronic migraine) trials.
Option A: Option A is incorrect because eptinezumab is humanized IgG1 (not fully human IgG2), targets the CGRP ligand (not the receptor), and is administered intravenously (not subcutaneously); the 90-day half-life from IgG2 FcRn recycling is fabricated — eptinezumab's half-life is approximately 27 days, consistent with standard IgG kinetics.
Option C: Option C is incorrect because eptinezumab is IgG1 (not IgG4 — IgG4 is galcanezumab's subclass), it is administered over 30 minutes (not 60 minutes), and it is dosed quarterly (not monthly); IgG4 Fab-arm exchange does not reduce half-life to 14 days.
Option D: Option D is incorrect because eptinezumab targets the CGRP ligand (not the receptor — erenumab is the receptor-targeting antibody), and no head-to-head trial has demonstrated superior efficacy of eptinezumab over the ligand-targeting antibodies attributable to dual-isoform blockade.
Option E: Option E is incorrect because eptinezumab is a humanized IgG1 (not fully human), administered intravenously (not subcutaneously by autoinjector), and has no hyaluronidase co-formulation; its clinical advantage is the IV route producing immediate Cmax, not a shortened Tmax after subcutaneous delivery.
13. The four approved anti-CGRP monoclonal antibodies share a common pharmacokinetic profile that reflects the general properties of therapeutic IgG antibodies. Which of the following correctly identifies the subcutaneous bioavailability range, time to peak plasma concentration after subcutaneous injection, terminal half-life, and elimination pathway shared by this class?
A) Subcutaneous anti-CGRP antibodies achieve a bioavailability of 95 to 100 percent because subcutaneous tissue lacks the proteolytic enzymes present in the gastrointestinal tract; they reach peak plasma concentrations within 6 to 12 hours of injection through rapid lymphatic uptake; their terminal half-life is approximately 7 to 10 days; and they are eliminated by glomerular filtration of intact antibody followed by tubular catabolism
B) Subcutaneous anti-CGRP antibodies achieve a bioavailability of approximately 5 to 15 percent due to extensive degradation by subcutaneous metalloproteases; they reach peak plasma concentrations within 12 to 24 hours via direct capillary absorption of the small fraction that escapes local degradation; their terminal half-life is approximately 14 days; and they are eliminated by hepatic Kupffer cell phagocytosis
C) Subcutaneous anti-CGRP antibodies achieve a bioavailability of approximately 50 to 80 percent; they reach peak plasma concentrations in 3 to 7 days via lymphatic absorption from the subcutaneous depot; their terminal half-life is approximately 27 to 31 days supported by FcRn-mediated recycling; and they are eliminated by proteolytic catabolism rather than hepatic CYP450 metabolism, producing no CYP-based drug interactions
D) Subcutaneous anti-CGRP antibodies achieve a bioavailability of approximately 50 to 80 percent via lymphatic absorption from the subcutaneous interstitial space; they reach peak plasma concentrations in approximately 3 to 7 days; their terminal half-life of approximately 27 to 31 days is maintained by FcRn-mediated endosomal recycling; and they are eliminated by proteolytic catabolism — not hepatic CYP450 metabolism — producing no pharmacokinetic drug interactions through CYP pathways and requiring no dose adjustments for renal or hepatic impairment in standard clinical practice
E) Subcutaneous anti-CGRP antibodies achieve a bioavailability of approximately 50 to 80 percent; they reach peak plasma concentrations in 3 to 7 days; their terminal half-life is approximately 27 to 31 days; and they are eliminated by a combination of hepatic CYP3A4 metabolism at standard doses and renal tubular secretion at supratherapeutic doses, which is why dose adjustment is required for patients with both severe hepatic impairment and renal impairment when using these agents at the 140 mg or 300 mg doses
ANSWER: D
Rationale:
The subcutaneous anti-CGRP monoclonal antibodies — erenumab, fremanezumab, and galcanezumab — share a pharmacokinetic profile characteristic of therapeutic IgG antibodies. Subcutaneous bioavailability ranges from approximately 50 to 80 percent, as large proteins cannot be directly absorbed into blood capillaries and must instead enter initial lymphatic capillaries and travel through the lymphatic network before reaching systemic circulation; some proteolytic degradation at the injection site accounts for the incomplete bioavailability. The rate-limiting lymphatic absorption produces a Tmax of approximately 3 to 7 days. The terminal half-life of approximately 27 to 31 days is maintained by FcRn (neonatal Fc receptor)-mediated recycling: antibodies internalized into endosomes bind FcRn at acidic pH, are protected from lysosomal degradation, and are returned to the cell surface where they are released at physiological pH. Elimination occurs by proteolytic catabolism — not by hepatic CYP450 enzymes or renal tubular transporters. This means the anti-CGRP antibodies produce no pharmacokinetic drug interactions through CYP pathways, and no dose adjustments are required for hepatic or renal impairment in standard clinical practice.
Option A: Option A is incorrect on all four parameters: bioavailability is not 95 to 100 percent (it is 50 to 80 percent), Tmax is not 6 to 12 hours (it is 3 to 7 days), half-life is not 7 to 10 days (it is 27 to 31 days), and elimination is not by glomerular filtration.
Option B: Option B is incorrect because bioavailability is not 5 to 15 percent (it is 50 to 80 percent), Tmax is not 12 to 24 hours via direct capillary absorption (lymphatic absorption requires 3 to 7 days), half-life is not 14 days, and elimination is not by hepatic Kupffer cell phagocytosis as the primary mechanism.
Option C: Option C is incorrect as written because it is incomplete: while its four stated pharmacokinetic parameters are accurate, it omits the clinically essential consequence that follows from the proteolytic catabolism pathway — namely, that no dose adjustments are required for renal or hepatic impairment in standard clinical practice; option D is the more complete and therefore correct answer because it explicitly states both the absence of CYP interactions and the absence of organ impairment dose adjustment requirements, which together constitute the full clinical pharmacokinetic advantage of the anti-CGRP antibody class over gepants.
Option E: Option E is incorrect because anti-CGRP antibodies are eliminated by proteolytic catabolism, not by CYP3A4 hepatic metabolism or renal tubular secretion; dose adjustments for hepatic or renal impairment are not required for standard clinical use of any approved anti-CGRP antibody.
14. Medication overuse headache (MOH) is a recognized complication of frequent acute migraine medication use. Which of the following correctly identifies the monthly use threshold above which triptans are considered to carry MOH risk, characterizes the gepant class MOH risk relative to triptans, and identifies the specific gepant evidence most relevant to this comparison?
A) Triptans carry MOH risk when used on more than 15 days per month for more than 3 months — the same threshold that applies to simple analgesics and NSAIDs; gepants carry an equivalent MOH risk to triptans because both inhibit trigeminal CGRP signaling, and the central sensitization mechanism driving MOH is identical regardless of whether CGRP inhibition is achieved by receptor antagonism or 5-HT1B-mediated presynaptic suppression of CGRP release
B) Triptans carry MOH risk when used on more than 10 days per month; gepants carry a higher MOH risk than triptans because the competitive reversible nature of gepant antagonism produces a CGRP rebound surge when plasma concentrations fall, and repeated rebound surges sensitize central pain pathways more effectively than the sustained moderate CGRP suppression produced by triptan-mediated presynaptic inhibition
C) Triptans carry MOH risk when used on more than 10 days per month for more than 3 months; gepants appear to have substantially lower MOH risk than triptans based on available clinical and post-marketing data; the most relevant evidence is that rimegepant used every other day for migraine prevention — a frequency that would clearly exceed triptan MOH thresholds — does not produce MOH, and this lower MOH risk profile applies to the gepant class broadly based on post-marketing surveillance
D) Triptans carry MOH risk when used on more than 10 days per month; gepants carry identical MOH risk to triptans because both drug classes are classified as high-risk agents for MOH by the International Headache Society (IHS), which updated its MOH classification in 2022 to include gepants alongside triptans in the 10-day-per-month overuse category following post-marketing reports of gepant-associated daily headache
E) Triptans carry MOH risk when used on more than 5 days per month, reflecting their high potency at 5-HT1B receptors; gepants carry MOH risk when used on more than 10 days per month, reflecting their lower receptor affinity requiring higher use frequency to produce the central sensitization driving MOH; the practical clinical difference is that patients can safely double their gepant use frequency compared to triptans before reaching the MOH threshold
ANSWER: C
Rationale:
Medication overuse headache develops when acute migraine medications are used on more than 10 to 15 days per month for more than 3 months. Triptans specifically carry well-established MOH risk at more than 10 treatment days per month — a lower threshold than simple analgesics and NSAIDs (more than 15 days per month). The gepant class appears to have substantially lower MOH risk than triptans based on the available evidence. The most clinically compelling evidence comes from rimegepant: it is approved for preventive use at 75 mg every other day — a dosing frequency of approximately 15 days per month — and this preventive schedule has not been associated with MOH, even when concurrent acute rimegepant use is included. This observation, combined with broader post-marketing surveillance data for the gepant class that does not establish gepants as a cause of MOH, supports the clinical position that gepants carry substantially lower MOH risk than triptans. This pharmacological property makes gepants a valuable option for transitioning patients away from triptan overuse while providing acute migraine coverage during the withdrawal process.
Option A: Option A is incorrect because the triptan MOH threshold is more than 10 days per month (not 15), and gepants do not carry equivalent MOH risk to triptans — their substantially lower MOH risk is the clinically important distinction.
Option B: Option B is incorrect because gepants have substantially lower MOH risk than triptans (not higher), and the CGRP rebound surge mechanism producing MOH from competitive reversible gepant antagonism has not been established clinically or described as a pharmacological phenomenon for this class.
Option D: Option D is incorrect because gepants have not been classified as high-risk MOH agents by the International Headache Society alongside triptans; available post-marketing data do not support including gepants in the same 10-day MOH risk category as triptans.
Option E: Option E is incorrect because the triptan MOH threshold is more than 10 days per month (not 5 days), and the framing that gepants simply allow double the use frequency before reaching an equivalent MOH threshold misrepresents the evidence — the gepant data suggest a qualitatively different (substantially lower) MOH risk rather than simply a higher numerical threshold.
15. Current guidance on the cardiovascular safety of CGRP-targeted therapies recommends caution in specific patient populations based on both mechanistic concerns and the deliberate exclusion of high-risk patients from pivotal clinical trials. Which of the following most accurately summarizes the cardiovascular patient population in whom anti-CGRP therapies — both gepants and monoclonal antibodies — should currently be avoided, and the reason the safety database is limited in this group?
A) Current guidance recommends avoiding anti-CGRP therapies in patients with recent major cardiovascular events — including myocardial infarction, stroke, and unstable angina — within approximately 3 to 6 months; the safety database is limited in this population because pivotal clinical trials deliberately excluded these patients due to the mechanistic concern that CGRP serves as a coronary vasodilator and cardioprotective peptide during ischemia, and preclinical data showed that CGRP antagonism worsened infarct size and impaired ischemic preconditioning in animal models
B) Current guidance recommends avoiding anti-CGRP therapies only in patients with active coronary vasospasm (Prinzmetal angina), because CGRP's primary cardiovascular role is prevention of coronary vasospasm; in all other cardiovascular conditions including myocardial infarction, stable angina, and stroke, anti-CGRP therapies are approved for use without restriction because the pivotal trials enrolled these patient populations and demonstrated cardiovascular safety across all comorbidity subgroups
C) Current guidance recommends avoiding anti-CGRP therapies indefinitely in any patient with a prior history of myocardial infarction, stroke, or peripheral vascular disease, regardless of how long ago the event occurred; the permanent contraindication reflects the irreversible loss of CGRP-mediated cardioprotection from permanent receptor downregulation following long-term anti-CGRP therapy exposure
D) Current guidance recommends avoiding anti-CGRP monoclonal antibodies — but not gepants — in patients with recent cardiovascular events, because gepants' short half-life of 6 to 11 hours allows rapid drug clearance if a cardiac event occurs during treatment, while the 27 to 31-day antibody half-life means significant CGRP blockade persists for weeks after discontinuation when cardioprotective CGRP signaling might be most needed
E) No specific cardiovascular population is identified by current guidance as requiring avoidance of anti-CGRP therapies, because the absence of vasoconstriction from both gepants and monoclonal antibodies means they carry no cardiovascular risk; the cardiovascular safety guidance simply notes that anti-CGRP therapies are preferred over triptans in any patient with cardiovascular disease and may be prescribed without additional restriction
ANSWER: A
Rationale:
The cardiovascular safety concern for CGRP-targeted therapy is mechanistically grounded in CGRP's established role as a coronary vasodilator and cardioprotective peptide. CGRP is released from perivascular cardiac sensory nerve terminals during myocardial ischemia, producing coronary vasodilation and direct cardiomyocyte protection through cAMP-mediated anti-apoptotic signaling. Preclinical animal studies demonstrated that CGRP receptor antagonism with early gepant candidates worsened myocardial infarct size and impaired ischemic preconditioning — a clear mechanistic signal. Because of this concern, all pivotal anti-CGRP monoclonal antibody clinical trials deliberately excluded patients with recent myocardial infarction (typically within 3 to 6 months), unstable angina, stroke, or uncontrolled hypertension. This deliberate exclusion means the safety database in these high-risk populations is limited and cannot be considered definitive. Current American Headache Society guidance translates this into a clinical recommendation to avoid anti-CGRP therapies in patients with recent major cardiovascular events within approximately 3 to 6 months, and to exercise clinical judgment with cardiology input in patients with stable cardiovascular disease beyond that window.
Option B: Option B is incorrect because the guidance is not limited to Prinzmetal angina, and patients with myocardial infarction, stroke, and unstable angina were not enrolled in pivotal trials — they were deliberately excluded, meaning safety in these populations cannot be claimed.
Option C: Option C is incorrect because anti-CGRP therapy is not permanently contraindicated in all patients with any prior cardiovascular history; the guidance recommends a time-limited deferral of approximately 3 to 6 months after a major event, not lifelong prohibition for all prior cardiovascular events.
Option D: Option D is incorrect because the guidance applies to both gepants and monoclonal antibodies — not only to antibodies; while the pharmacokinetic rationale about half-life differences has some theoretical basis, current guidance does not create a gepant-only exception, and both drug classes are subject to the same cardiovascular caution in patients with recent major events.
Option E: Option E is incorrect because the absence of vasoconstriction does not eliminate the cardiovascular safety concern — the concern is not about vasoconstriction but about loss of CGRP-mediated cardioprotection; current guidance explicitly identifies patients with recent major cardiovascular events as a population in whom anti-CGRP therapy should be avoided.
16. Anti-CGRP monoclonal antibodies do not cross the blood-brain barrier yet are clinically effective migraine preventives. Which of the following correctly identifies the anatomical sites of CLR/RAMP1 CGRP receptor expression that are therapeutically relevant and explains why peripheral CGRP blockade at these sites is sufficient for clinical efficacy?
A) CLR/RAMP1 receptors relevant to migraine are expressed exclusively within the central nervous system — on neurons of the trigeminal nucleus caudalis and on cells of the locus coeruleus; anti-CGRP antibodies are effective despite not crossing the blood-brain barrier because they reduce systemic CGRP levels sufficiently to lower the concentration gradient driving CGRP diffusion across the blood-brain barrier, indirectly reducing central CGRP receptor activation
B) CLR/RAMP1 receptors relevant to migraine are expressed on cortical neurons in the occipital cortex; anti-CGRP antibodies reach these receptors through the circumventricular organs (area postrema and median eminence), which lack a complete blood-brain barrier and allow passage of large proteins from the systemic circulation into the adjacent cortical parenchyma, explaining antibody efficacy despite general blood-brain barrier exclusion
C) CLR/RAMP1 receptors relevant to migraine are expressed only on vascular smooth muscle cells of the dural arteries and middle meningeal artery; anti-CGRP antibodies block CGRP-mediated dilation of these vessels, and because the dural vasculature is directly accessible from the systemic circulation without any blood-brain barrier, complete migraine prevention is achieved through vascular CGRP blockade alone without any neuronal component
D) CLR/RAMP1 receptors relevant to migraine are expressed on the endothelial cells of the blood-brain barrier itself; CGRP released during migraine increases blood-brain barrier permeability, and anti-CGRP antibodies prevent this permeability increase, thereby indirectly preventing the passage of other inflammatory mediators into the CNS that would otherwise drive the headache phase
E) CLR/RAMP1 CGRP receptors relevant to migraine are expressed at three key sites: the meningeal dural vasculature (where CGRP produces the peripheral vasodilation and nociceptor sensitization of the headache phase), the trigeminal ganglion (the cell body source of both peripheral and central CGRP-containing projections, lying anatomically outside the blood-brain barrier in Meckel's cave), and neurons of the trigeminal nucleus caudalis (the central sensitization site); peripheral blockade is sufficient because the trigeminal ganglion — accessible to circulating antibody — is the source of CGRP release at both downstream sites
ANSWER: E
Rationale:
The therapeutic rationale for anti-CGRP monoclonal antibody efficacy despite blood-brain barrier exclusion rests on the anatomical accessibility of the key pharmacological targets. Three sites of CLR/RAMP1 expression are central to migraine pathophysiology. First, the meningeal dural vasculature: CGRP released from peripheral trigeminal terminals causes dilation of dural vessels, plasma extravasation, and sensitization of meningeal nociceptors, directly initiating the headache phase. This vascular target is in the periphery, fully accessible to circulating antibody. Second, the trigeminal ganglion: the pseudounipolar cell bodies of the trigeminal afferents in the trigeminal ganglion (TGG) lie anatomically outside the blood-brain barrier in Meckel's cave — they are not protected by CNS tight junctions and are freely accessible to circulating macromolecules. The trigeminal ganglion is the source of both the peripheral projections (to meningeal vasculature) and the central projections (to the trigeminal nucleus caudalis, TNC). By blocking CGRP at the level of the ganglion and peripheral terminals, antibodies can reduce the CGRP signal available for release at both downstream sites. Third, the trigeminal nucleus caudalis: the central synapse where trigeminal afferents terminate in the brainstem, contributing to central sensitization and allodynia — this site is within the CNS and inaccessible to antibody, but the upstream ganglionic blockade limits the CGRP-mediated signal reaching it.
Option A: Option A is incorrect because the therapeutic sites are not exclusively within the CNS; the meningeal vasculature and the trigeminal ganglion are peripheral sites critical to efficacy, and the concentration-gradient mechanism for indirect central CGRP reduction does not reflect the established pharmacological explanation.
Option B: Option B is incorrect because the cortical neurons of the occipital cortex are not the established therapeutic target for anti-CGRP antibodies, and the circumventricular organ pathway does not provide access to cortical parenchyma for 147 to 150 kDa IgG antibodies in a clinically meaningful way.
Option C: Option C is incorrect because the therapeutic target is not limited to vascular smooth muscle of dural arteries; neuronal CLR/RAMP1 receptors at the trigeminal ganglion are important targets, and the trigeminal ganglion's accessibility outside the BBB — not just the dural vasculature — is central to the pharmacological explanation for antibody efficacy.
Option D: Option D is incorrect because CLR/RAMP1 receptor expression on blood-brain barrier endothelium is not the established therapeutic target for anti-CGRP antibodies in migraine, and prevention of barrier permeability change is not the primary mechanism of clinical efficacy.
This Web-based pharmacology and disease-based integrated teaching site is based on reference materials that are believed reliable and consistent with standards accepted at the time of development.
Possibility of error and on-going research and development in medical sciences do not allow assurance that the information contained herein is in every respect accurate or complete.
Users should confirm the information contained herein with other sources.
This site should only be considered as a teaching aid for undergraduate and graduate biomedical education and is intended only as a teaching site.
Information contained here should not be used for patient management and should not be used as a substitute for consultation with practicing medical professionals.
Users of this website should check the product information sheet included in the package of any drug they plan to administer to be certain that the information contained in this site is accurate and that changes have not been made in the recommended dose or in the contraindications for administration.
Medical or other information thus obtained should not be used as a substitute for consultation with practicing medical or scientific or other professionals.